ArticleAnnals of laboratory medicine2023
Serotype Distribution and Antimicrobial Resistance of
Article in Annals of laboratory medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 42 citations in OpenAlex.
- A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR).Human vaccines & immunotherapeutics · 2024Trial
- Changing Epidemiology of Severe Pneumococcal Pneumonia in Adults at a Tertiary Hospital between 2010 and 2024.Tuberculosis and respiratory diseases · 2026Article
- Article
- Global Antimicrobial Non-Susceptibility Patterns ofInfection and drug resistance · 2026Review
- Article
- Invasive pneumococcal disease by serotype 23B in an asplenic unvaccinated patient: A case report.IDCases · 2026Article
- Serotype distribution among adults with community-acquired pneumococcal pneumonia in Japan between 2019 and 2022: A multicenter observational study.Human vaccines & immunotherapeutics · 2025Observational
- Global distribution and characteristics of pneumococcal serotypes in adults.Human vaccines & immunotherapeutics · 2025Review
- Back to the future? Drastic drop in serotype 19A carriage in daycare centers within two years after a second switch to PCV13 in Belgium.Human vaccines & immunotherapeutics · 2025Article
- Experimental study on factors influencing low identification rates and spectral quality ofMicrobiology spectrum · 2025Article
- Distribution of serotypes and antibiotic resistance profiles of Streptococcus pneumoniae in hospitalized adult patients: aretrospective multicenter surveillance in China (2018-2019).BMC infectious diseases · 2025Article
- Genomic analysis and pneumococcal population dynamics across PCV implementation in South Korea, 1997-2023.Microbial genomics · 2025Article
- Understanding current challenges of antibiotic resistance to find new solutions for 2050: scientific, medical and political issues.Archives of microbiology · 2025Review
- Review
- Update on the evolving landscape of pneumococcal capsule types: new discoveries and way forward.Clinical microbiology reviews · 2025Review
- The Evolution of the Antimicrobial Resistance ofAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Article
- Pneumococcal disease burden in high-risk older adults: Exploring impact of comorbidities, long-term care facilities, antibiotic resistance, and immunization policies through a narrative literature review.Human vaccines & immunotherapeutics · 2024Review
- Antimicrobial Resistance ofInfection & chemotherapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: Results: Among the 411 Conclusions: Non-PCV13 serotypes are increasing among invasive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.